April 27th 2024
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Diagnostic Assay Submitted for FDA Approval in Ovarian Cancer Indication
January 24th 2020Myriad Genetics, Inc, has submitted a supplementary premarket approval application to the FDA for the myChoice CDx test for use in predicting outcomes for women with frontline platinum-responsive advanced ovarian cancer who are treated with niraparib, a PARP inhibitor, according to a press release from Myriad Genetics, Inc., the manufacturer of the test.
Read More
Dasatinib Combination Leads to Superior Event-Free Survival Rates in Ph-Positive Pediatric ALL
January 22nd 2020Dasatinib, a second-generation Abl-tyrosine kinase inhibitor, used concurrently with an intensive chemotherapy regimen yields superior outcomes compared with imatinib plus chemotherapy in pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, according to the results from the first randomized phase III clinical trial comparing the 2 drugs in this patients <a>population</a>.
Read More
Niraparib Maintenance Improves PFS in Frontline Ovarian Cancer
January 20th 2020Antonio Gonzalez Martín, MD, discusses the results from the phase III PRIMA study, which evaluated the PARP inhibitor niraparib versus placebo as a frontline treatment of patients with newly diagnosed ovarian cancer who responded to platinum-based chemotherapy.
Watch
Integrating a geriatric assessment into the care of older adults who are receiving cancer treatment in communi­ty oncology practices improves patient and caregiver satisfaction and encourages commu­nication about aging-related concerns, accord­ing to results of a clinical trial that enrolled 541 patients with advanced cancer.
Read More
Expert Says Phase III Avelumab Trial is First Step of Immunotherapy Story in Ovarian Cancer
January 17th 2020In an interview with Targeted Oncology, Eric Pujade-Lauraine, MD, PhD, discussed the data from the JAVELIN Ovarian 200 trial, which he presented at the 2019 Society of Gynecologic Oncology Annual Meeting. He highlighted the need for biomarkers in this space, as well as some data from an exploratory analysis from this trial.
Read More
FDA Grants Priority Review to Olaparib Plus Bevacizumab for Frontline Ovarian Cancer
January 14th 2020The supplemental New Drug Application for olaparib, a PARP inhibitor, in combination with bevacizumab has been granted Priority Review by the FDA as maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy, based on the results from the phase III PAOLA-1 trial, according to a press release from AstraZeneca and Merck & Co, Inc.1<br />
Read More
Telehealth Delivers Access to Care and Cutting-Edge Clinical Research to Rural Areas
January 11th 2020The present and future benefits of telehealth in oncology can be observed through Tahoe For­est Cancer Center and its affiliation with the UC Davis Cancer Center, use of other remote clinics, and participation in virtual tumor boards. Even though there are roadblocks to telehealth reaching more locations and more patients, the potential benefit warrants the time needed to get over those hurdles.
Read More
Siravatinib/Tislelizumab Signals Efficacy in Patients With Platinum-Resistant Ovarian Cancer
December 14th 2019Preliminary data showed that the combination of sitravatinib and tislelizumab is well tolerated and may promote antitumor activity when administered to patients with platinum-resistant ovarian cancer, according to a press release from BieGene, Ltd, which reported data from a phase Ib study at the 2019 European Society of Oncology Immuno-Oncology Congress in Geneva, Switzerland.<br />
Read More
Rationalizing the Use of Pembrolizumab/Bevacizumab in Women With Recurrent Ovarian Cancer
December 4th 2019Emese Zsiros, MD, PhD, FACOG, assistant professor of oncology, Department of Gynecologic Oncology, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center explains the rationale for the a phase II study, which combined pembrolizumab with bevacizumab in patients with recurrent ovarian cancer. Zsiros presented data on the study in early 2019 at the SGO Annual Meeting.
Watch
MRTX849 Shows Safety, Tolerability in Treating KRAS G12C
November 29th 2019In patients whose solid<strong> </strong>tumors harbor a mutation in <em>KRAS </em>G12C, therapy with MRTX849 has produced promising responses and acceptable toxicity across 3 tumors types, according to data presented at the 2019 American Association for Cancer Research–National Cancer Institute–European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics.
Read More
Rucaparib May Improve PFS in Patients With Ovarian Cancer
November 22nd 2019Jonathan Ledermann, MD, professor of oncology, UCL Cancer Institute, University College London, discusses the results of a subanalysis from the phase III ARIEL trial of rucaparib maintenance treatment for patients with recurrent ovarian carcinoma.
Watch
FGFR2 Emerges as a Promising Target in Cholangiocarcinoma
November 20th 2019Given the frequency of <em>FGFR2</em> alterations in intrahepatic cholangiocarcinoma, investigators have identified it as a potential prognostic indicator of survival and a rational target of systemic cancer therapies.
Read More
In an interview with Targeted Oncology, Kathleen Moore, MD, discussed the data surrounding mirvetuximab soravtansine in this patient population and the plans to reevaluate the ADC following the results from the FORWARD I/GOG 3011 clinical trial. She also highlighted other areas of investigation for women with platinum-resistant ovarian cancer.
Read More